Sarcouncil Journal of Medical Sciences

Abstract: This research evaluates serum calcium as a cost-effective, accessible biomarker for pediatric acute lymphoblastic leukemia (ALL). A study of 80 participants in Sudan revealed that ALL patients have significantly lower serum calcium levels than healthy controls. This hypocalcemia appears to be a consistent metabolic feature of the disease, independent of the patient's age or gender. Furthermore, calcium levels did not vary significantly across different FAB subtypes or chemotherapy cycles. Interestingly, serum calcium showed a strong correlation with disease duration, with lower levels found in the early stages of the illness. These early deficits may stem from increased tumor activity, systemic inflammation, and chemotherapy-induced metabolic disruptions. The findings emphasize that routine calcium monitoring is vital to prevent complications like decreased bone metabolism and cardiac issues. Ultimately, the study advocates for integrated metabolic monitoring and supportive care to improve clinical management in pediatric leukemia.